Literature DB >> 19158603

Designer natriuretic peptides.

Candace Y W Lee1, Hsiao Lieu, John C Burnett.   

Abstract

Designer natriuretic peptides (NPs) are novel hybrid peptides that are engineered from the native NPs through addition, deletion, or substitution of amino acid(s) with a goal toward optimization of pharmacological actions while minimizing undesirable effects. In this article, selected peptides that were designed in our laboratory are reviewed, and future directions for research and development of designer NPs are discussed.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19158603      PMCID： PMC3129707          DOI： 10.2310/JIM.0b013e3181946fb2

Source DB:  PubMed          Journal:  J Investig Med        ISSN： 1081-5589            Impact factor:   2.895


  44 in total

Review 1.  Atrial natriuretic peptides: anticancer agents.

Authors:  David L Vesely
Journal:  J Investig Med       Date:  2005-11       Impact factor: 2.895

2.  Natriuretic peptides: a new lipolytic pathway in human adipocytes.

Authors:  C Sengenès; M Berlan; I De Glisezinski; M Lafontan; J Galitzky
Journal:  FASEB J       Date:  2000-07       Impact factor: 5.191

Review 3.  Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease.

Authors:  Alessandro Cataliotti; Horng H Chen; Kenneth D James; John C Burnett
Journal:  Trends Cardiovasc Med       Date:  2007-01       Impact factor: 6.677

4.  Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure.

Authors:  Gurminder Singh; Rhoda E Kuc; Janet J Maguire; Mark Fidock; Anthony P Davenport
Journal:  Circ Res       Date:  2006-06-15       Impact factor: 17.367

5.  Receptor subtypes for vasonatrin peptide in renal glomeruli and arteries.

Authors:  Geoffrey E Woodard; Xiaohong Li; John Brown; Juan A Rosado
Journal:  Regul Pept       Date:  2005-07-15

6.  Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy.

Authors:  Mitsuru Suwa; Yoshihiko Seino; Yoshikata Nomachi; Shinsuke Matsuki; Kazuteru Funahashi
Journal:  Circ J       Date:  2005-03       Impact factor: 2.993

7.  C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction.

Authors:  Takeshi Soeki; Ichiro Kishimoto; Hiroyuki Okumura; Takeshi Tokudome; Takeshi Horio; Kenji Mori; Kenji Kangawa
Journal:  J Am Coll Cardiol       Date:  2005-02-15       Impact factor: 24.094

8.  Haemodynamic and clinical effects of ularitide in decompensated heart failure.

Authors:  Veselin Mitrovic; Petar M Seferovic; Dejan Simeunovic; Arsen D Ristic; Milutin Miric; Valentin S Moiseyev; Zhanna Kobalava; Klaus Nitsche; Wolf-Georg Forssmann; Hartmut Lüss; Markus Meyer
Journal:  Eur Heart J       Date:  2006-10-30       Impact factor: 29.983

9.  Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure.

Authors:  Alessandro Cataliotti; John A Schirger; Fernando L Martin; Horng H Chen; Paul M McKie; Guido Boerrigter; Lisa C Costello-Boerrigter; Gail Harty; Denise M Heublein; Sharon M Sandberg; Kenneth D James; Mark A Miller; Navdeep B Malkar; Karen Polowy; John C Burnett
Journal:  Circulation       Date:  2005-08-01       Impact factor: 29.690

10.  Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure.

Authors:  Horng H Chen; Margaret M Redfield; Lynda J Nordstrom; Darlene P Horton; John C Burnett
Journal:  J Card Fail       Date:  2004-04       Impact factor: 5.712
View more
  7 in total

1.  Evolving treatment strategies for management of cardiorenal syndrome.

Authors:  Sanjay Dandamudi; Horng H Chen
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-12

Review 2.  Guanylyl cyclase / atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation.

Authors:  Kailash N Pandey
Journal:  Can J Physiol Pharmacol       Date:  2011-08-04       Impact factor: 2.273

3.  Impaired sinoatrial node function and increased susceptibility to atrial fibrillation in mice lacking natriuretic peptide receptor C.

Authors:  Emmanuel E Egom; Kimberly Vella; Rui Hua; Hailey J Jansen; Motahareh Moghtadaei; Iuliia Polina; Oleg Bogachev; Rhea Hurnik; Martin Mackasey; Sara Rafferty; Gibanananda Ray; Robert A Rose
Journal:  J Physiol       Date:  2015-01-12       Impact factor: 5.182

Review 4.  Progress toward genetic tailoring of heart failure therapy.

Authors:  John H Lillvis; David E Lanfear
Journal:  Curr Opin Mol Ther       Date:  2010-06

Review 5.  CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease.

Authors:  Paul M McKie; S Jeson Sangaralingham; John C Burnett
Journal:  Curr Heart Fail Rep       Date:  2010-09

Review 6.  Novel drug mechanisms in development for heart failure.

Authors:  Soidjon D Khodjaev; John R Teerlink; Fady I Malik
Journal:  Pflugers Arch       Date:  2014-05-06       Impact factor: 3.657

Review 7.  Genetic Ablation and Guanylyl Cyclase/Natriuretic Peptide Receptor-A: Impact on the Pathophysiology of Cardiovascular Dysfunction.

Authors:  Kailash N Pandey
Journal:  Int J Mol Sci       Date:  2019-08-14       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.